AC480, a novel EGFR and HER2 inhibitor, administered before and during exposure to gamma radiation, was discovered to enhance the radiosensitivity of HNSCC cells and significantly reduce tumor size in vivo (59). The gene discussed is EGFR; the disease is neoplasm.